Harnessing the Power of RWD in China

In 2018, China made the cultivation of healthcare big data a national priority. Such data represent a tremendous opportunity for pharma companies to optimize their pricing strategies in China. This is important because for most drugs, China’s national reimbursement scheme requires huge discounts from launch prices. Thus, high-cost, innovative drugs can face significant barriers to widespread patient adoption. LEK Consulting and LinkDoc Technology recently published a report  that demonstrates several ways to develop a more impactful and nuanced pricing strategy through assessing market potential, predicting drug adoption and determining indication trade-offs. Access the full report here.

(Source: The Pharma Letter, September 28, 2020)